Selegiline (L-Deprenyl) and L-Dopa Treatment of Parkinson's Disease: A Double-Blind Trial

Mitsuo TAKAHASHI; Ryoichi YUASA; Terukuni IMAI; Hisao TACHIBANA; Shiro YORIFUJI; Yusaku NAKAMURA; Nobuya OGAWA

doi:10.2169/internalmedicine.33.517

Mitsuo TAKAHASHI, Ryoichi YUASA, Terukuni IMAI, Hisao TACHIBANA, Shiro YORIFUJI, Yusaku NAKAMURA, Nobuya OGAWA

Author information

Keywords: selegiline (L-deprenyl), monoamine oxidase B inhibitor (MAO B-I), double-blind study, Parkinson's disease

JOURNAL FREE ACCESS

1994 Volume 33 Issue 9 Pages 517-524

DOI https://doi.org/10.2169/internalmedicine.33.517

Details

Abstract

To confirm the clinical utility of selegiline (L-deprenyl), a selective inhibitor of monoamine oxidase B, as an anti-Parkinson's disease (PD) agent, the first Japanese multi-center, double-blind comparative study of this drug was conducted. The subjects were patients who had responded poorly or suffered with other problems related to L-dopa treatment. A total of 112 patients in two groups, one given selegiline at a dose of 7.5 mg/day (Group D, n=60) and another given a placebo (Group P, n=52), were compared over an 8-week treatment period. The percentage patients showing "moderate improvement" or better was 34.5% in Group D, while that in Group P was 11.5 % (P<0.01). In the assessment of overall safety, 66.7 % in Group D showed no adverse reactions, which was not significantly different from the result of 78.9% for Group P.
(Internal Medicine 33: 517-524, 1994)

Corresponding author

Register with J-STAGE for free!